DB:C6K

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cerecor Inc., a pharmaceutical company, focuses on pediatric health care.


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Cerecor's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: C6K's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

45.5%

C6K

-0.6%

DE Pharmaceuticals

4.3%

DE Market


1 Year Return

-33.4%

C6K

19.2%

DE Pharmaceuticals

0.3%

DE Market

Return vs Industry: C6K underperformed the German Pharmaceuticals industry which returned 19.2% over the past year.

Return vs Market: C6K underperformed the German Market which returned 0.3% over the past year.


Shareholder returns

C6KIndustryMarket
7 Day45.5%-0.6%4.3%
30 Day32.4%-1.7%7.4%
90 Day10.5%6.7%-0.2%
1 Year-33.4%-33.4%23.1%19.2%2.0%0.3%
3 Yearn/a24.9%10.5%-5.0%-12.3%
5 Yearn/a29.3%6.9%4.2%-9.2%

Price Volatility Vs. Market

How volatile is Cerecor's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cerecor undervalued compared to its fair value and its price relative to the market?

7.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate C6K's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate C6K's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: C6K is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: C6K is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate C6K's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: C6K is overvalued based on its PB Ratio (7.5x) compared to the XE Pharmaceuticals industry average (3.3x).


Next Steps

Future Growth

How is Cerecor forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

40.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: C6K is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: C6K is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: C6K is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: C6K's revenue (58.2% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: C6K's revenue (58.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if C6K's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cerecor performed over the past 5 years?

-32.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: C6K is currently unprofitable.

Growing Profit Margin: C6K is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: C6K is unprofitable, and losses have increased over the past 5 years at a rate of -32.2% per year.

Accelerating Growth: Unable to compare C6K's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: C6K is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7%).


Return on Equity

High ROE: C6K has a negative Return on Equity (-129.99%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cerecor's financial position?


Financial Position Analysis

Short Term Liabilities: C6K's short term assets ($25.5M) exceed its short term liabilities ($15.3M).

Long Term Liabilities: C6K's short term assets ($25.5M) exceed its long term liabilities ($3.2M).


Debt to Equity History and Analysis

Debt Level: C6K is debt free.

Reducing Debt: C6K currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: C6K has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: C6K has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.3% each year.


Next Steps

Dividend

What is Cerecor's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate C6K's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate C6K's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if C6K's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if C6K's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of C6K's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.2yrs

Average management tenure


CEO

Mike Cola (59yo)

0.25

Tenure

Mr. Michael F. Cola, also known as Mike, serves as Chief Executive Officer and Director at Cerecor Inc. since February 3, 2020. Mr. Cola serves as President at Cerecor Inc. Mr. Cola had been the Chief Exec ...


Leadership Team

NamePositionTenureCompensationOwnership
Sol Barer
Executive Chairman0.083yrUS$9.17kno data
Michael Cola
CEO, President & Director0.25yrno data0.11% $200.4k
Solomon Snyder
Founder and Chairman of Scientific Advisory Boardno datano datano data
Barbara Slusher
Founder and Member of Scientific Advisory Boardno datano datano data
Christopher Sullivan
Interim Chief Financial Officer0.083yrno datano data
Garry Neil
Chief Scientific Officer0.17yrno data0.11% $191.2k
James Harrell
Chief Commercial Officer1.33yrsUS$729.91k0.018% $30.7k
Stephen Thomas
VP & Head of Discovery1.67yrsno datano data
H. Wilkins
Chief Medical Officer0.17yrno datano data
Mariam Morris
Consultant1.83yrsUS$687.47kno data

0.2yrs

Average Tenure

56.5yo

Average Age

Experienced Management: C6K's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Sol Barer
Executive Chairman0.083yrUS$9.17kno data
Michael Cola
CEO, President & Director0.25yrno data0.11% $200.4k
Solomon Snyder
Founder and Chairman of Scientific Advisory Boardno datano datano data
Barbara Slusher
Founder and Member of Scientific Advisory Boardno datano datano data
Philip Gutry
Independent Director5.08yrsUS$193.83kno data
Gunnar Magnus Severus Persson
Independent Director8.08yrsUS$183.76kno data
Ronald Borchardt
Member of Scientific Advisory Boardno datano datano data
Anne Young
Member of Scientific Advisory Boardno datano datano data
Keith Schmidt
Lead Independent Director0.75yrUS$403.95kno data
Dennis Liotta
Member of Scientific Advisory Boardno datano datano data

0.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: C6K's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.5%.


Top Shareholders

Company Information

Cerecor Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cerecor Inc.
  • Ticker: C6K
  • Exchange: DB
  • Founded: 2011
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$192.733m
  • Listing Market Cap: US$174.327m
  • Shares outstanding: 65.89m
  • Website: https://www.cerecor.com

Number of Employees


Location

  • Cerecor Inc.
  • 540 Gaither Road
  • Suite 400
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CERCNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2015
C6KDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2015

Biography

Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-406 for the treatment of Parkinson’s disease; CERC-425, an orally active small molecule; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and CERC-913, a protide nucleotide for the treatment of mitochondrial disorder. It also developing preclinical therapies CERC-801, CERC-802, and CERC-803 for the treatment of inherited metabolic disorders. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/29 06:16
End of Day Share Price2020/05/28 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.